Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Processa Pharmaceuticals and keeping the price target at $2.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ram Selvaraju has given his Buy rating due to a combination of factors that highlight Processa Pharmaceuticals’ strategic focus and potential for growth. The company has prioritized the clinical development of its lead oncology asset, NGC-Cap, which is currently in a Phase 2 trial for advanced or metastatic breast cancer. This trial, designed to evaluate safety and efficacy, is expected to yield interim data by early Q4 2025, potentially building on positive results from previous studies.
Additionally, Processa is actively pursuing strategic initiatives such as designing a new adaptive pivotal Phase 3 study for PCS499 in kidney disease and establishing a subsidiary to enhance flexibility in capital raising and partnerships. The partnership with Intact Therapeutics for the PCS12852 prokinetic agent further exemplifies Processa’s strategy to monetize non-core assets while retaining upside potential. These efforts, combined with the termination of the PCS3117 license to focus resources more effectively, contribute to the positive outlook reflected in Selvaraju’s Buy rating and the 12-month price target of $2.